Featured Outsourcing Editorial
-
Lean Thinking For Pharma — Flow Without Facility Upheaval
4/28/2025
Lean offers manufacturers a host of efficiencies, but they don't all work for GMP. Here are some ideas for translating best practices for a highly-regulated industry.
-
A Checklist For Mechanism-Based Potency Testing In Cell Therapy
4/25/2025
New research concludes that potency cannot be decoupled from a product's mechanism of action because surrogate markers fail to capture functional relevance.
-
PDG-FDA Town Hall Notes — DSCSA Readiness Is At Hand
4/24/2025
Data quality and exceptions handling were key discussion points during a March PDG-FDA town hall, where stakeholders shared updates on progress and unfinished work.
-
The Strategic Role Of Cost Modeling In Pharmaceutical Procurement
4/24/2025
Selecting a CDMO depends on price, geography, expertise, and other variables. While price is often a key motivation for the decision, it is production cost that should be carefully considered. An independent analysis can be of great help. An Outsourced Pharma Board member presents some scenarios.
-
ICH Revises Q1 Guideline, Advancing Stability Testing Standards
4/24/2025
In April 2025, the International Council for Harmonisation (ICH) released draft ICH Q1: Stability Testing of Drug Substances and Drug Products for public consultation. This new draft guideline represents the first major overhaul of global stability testing standards in over two decades.
-
Common Manufacturing Challenges For LBP Formulations
4/23/2025
As more companies explore live biotherapeutic products, ensuring stability is likely to be front and center with unique challenges for oral and topical applications.
-
What CDMOs Wish Biotechs Knew Before Submitting An RFP
4/23/2025
This author has worked with CDMOs across different programs and therapeutic modalities. Each experience reinforced the same lesson: a strong RFP can make or break a partnership.
-
8 Actions To Redefine Sponsor–CDMO Relationships
4/22/2025
When viewing a CDMO as merely a service provider, interactions are often limited to completing tasks. This mindset can stifle innovation and problem-solving.
-
We Must Rethink The Solvents We Use For Peptide Synthesis
4/21/2025
While the effectiveness of GLP-1 in weight loss is good news, the use of organic solvents in the GLP-1 synthesis and purification process is a growing pain that needs to be addressed.
-
Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
4/17/2025
The U.S. tariffs on trading partners bring a whole new set of challenges, but there are tactics and strategies companies can deploy to help offset the cost and operational impacts.